| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.6 | 0.2 |
| Gross profit | 0.6 | 0.2 |
| Profit before tax | -4.5 | -3.5 |
| Net income | -4.5 | -3.5 |
| EPS (diluted, $ a share) | $-1.03 | $-1.30 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +217.5% |
|---|---|
| Gross margin | 92.4% |
10-Q filed with the SEC, NASDAQ: ICU. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
SeaStar Medical Holding Corp: key numbers
- Share price
- $0.7810Close, Nov 17
- Market cap
- $4.15M
- Shares outstanding
- 5.32MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from SeaStar Medical Holding Corp
All →SeaStar Medical Holding Financial Results
SeaStar Medical reported Q3 2026 financial results, highlighted by a 247% increase in net revenue to $635,000 driven by adoption of its QUELIMMUNE therapy. The company also announced that its NEUTRALIZE-AKI pivotal clinical trial for adult patients is nearly 75% enrolled and it has submitted the first module of its PMA application to the FDA.
- Term
- Q3 2026
“The strength of the QUELIMMUNE therapy adoption in this ultra-rare pediatric AKI market provides great promise for our pipeline indications. And we continue to build momentum in educating the critical care pediatric health care community.”
Eric Schlorff, CEO of SeaStar Medical
“The NEUTRALIZE-AKI pivotal clinical trial has enrolled nearly 75% of its intended 339 patients, and we have already submitted the first module of the premarket approval application to the FDA in hopes that our modular submission will speed this potential approval.”
Eric Schlorff, CEO of SeaStar Medical
SeaStar Medical Holding Business Update
SeaStar Medical announced that the FDA's Center for Biologics Evaluation and Research (CBER) determined the QUELIMMUNE Pediatric SAVE Surveillance Registry has fulfilled its post-approval study requirements. This decision allows hospitals to use the QUELIMMUNE therapy for pediatric sepsis-associated acute kidney injury without the research infrastructure previously required by the registry, significantly expanding patient access.
- Counterparty
- FDA
SeaStar Medical Holding Capital Raise of $3.3M
SeaStar Medical entered into agreements with warrant holders to exercise outstanding warrants for 854,002 shares at a reduced price of $3.866 per share, generating $3.3 million in gross proceeds. In exchange for the cash exercise, the company issued new unregistered Series A and Series B warrants for an additional 1,708,004 shares. The proceeds are intended for general corporate purposes, including working capital and capital expenditures.
- Value
- $3.3M
- Counterparty
- H.C. Wainwright & Co., LLC